SMALL CELL LUNG CANCER

This study tests a new three-drug combination (ADI-PEG 20, gemcitabine, and docetaxel) in people with small cell or non-small cell lung cancer whose disease has worsened after initial treatment. The first part of the study finds the safest dose, and the second part checks how wel…

This study tests whether adding lurbinectedin to atezolizumab as maintenance therapy helps people with extensive-stage small-cell lung cancer live longer without their cancer growing. Participants must have stable disease or better after initial chemotherapy. The trial compares t…

This early-phase study tests an experimental oral drug, BBI-355, in people with advanced solid tumors (like certain breast, ovarian, lung, and other cancers) that have extra copies of cancer-driving genes. The goal is to find a safe dose and see if BBI-355, alone or with other ta…

This study tests an experimental drug called HPN328, alone or with other medicines, in people with advanced small-cell lung cancer or neuroendocrine cancers that have DLL3 protein. The goal is to find the safest dose and see if it helps shrink tumors. About 232 adults will take p…

This early-phase trial studies whether adding radiation to the chest followed by immunotherapy drugs (durvalumab alone or with tremelimumab or olaparib) can safely control extensive-stage small cell lung cancer after initial chemotherapy. About 25 adults whose cancer did not wors…

This study is for people with advanced solid tumors (like lung, bladder, or skin cancer) that have stopped responding to standard immunotherapy drugs called PD-1/PD-L1 inhibitors. Researchers are testing a new combination of immune-boosting drugs to see if they can shrink tumors …

This study tests whether adding an experimental drug (AZD2811) to the immunotherapy durvalumab can help keep extensive-stage small-cell lung cancer from growing after initial treatment. About 31 adults with this aggressive cancer will receive the combination as maintenance therap…

This study tests whether adding the immunotherapy drug atezolizumab after standard chemo-radiotherapy helps people with limited-stage small-cell lung cancer live longer. About 212 participants will receive either atezolizumab or no additional treatment. The goal is to see if the …

This study tests whether adding the immunotherapy drugs durvalumab (with or without tremelimumab) after standard chemoradiation can help people with limited-stage small cell lung cancer live longer without their cancer growing. About 730 participants who completed initial treatme…

This early-stage study tests a new treatment called AMG 119 for adults with small cell lung cancer that has returned or not responded to standard chemotherapy. The treatment uses specially engineered immune cells (CAR T cells) to attack the cancer. The main goals are to check saf…

This study tests a new drug called PF-07104091, alone or with other medicines, in people with advanced breast, lung, or ovarian cancer that has spread or come back. The goal is to find a safe dose and see if it shrinks tumors. About 157 adults will take part, and the drug is give…

This study tests a new drug called BNT327 combined with chemotherapy for people with a hard-to-treat type of lung cancer (small-cell lung cancer). About 110 adults with either newly diagnosed or previously treated cancer will take part. The goal is to see if the combo shrinks tum…

This study tests whether adding tarlatamab to durvalumab helps people with extensive-stage small-cell lung cancer live longer. About 563 adults who finished initial chemotherapy and durvalumab without their cancer getting worse will be randomly assigned to get either the combinat…

This study tests a drug called tarlatamab in people with limited-stage small cell lung cancer whose cancer has not grown after standard chemotherapy and radiation. About 404 participants will receive either tarlatamab or a placebo to see if the drug can delay cancer progression a…

This study tests whether adding chest radiation to an immunotherapy drug (durvalumab) after initial chemotherapy can help people with advanced small cell lung cancer live longer without the disease getting worse. About 46 adults with extensive-stage small cell lung cancer will re…

This study compares a new drug, BL-B01D1, to the standard drug topotecan in 722 adults with small cell lung cancer that came back after prior treatments. The goal is to see if BL-B01D1 helps people live longer. Participants must have already tried immunotherapy and chemotherapy w…

This study tests a new drug called SKB264 in people with advanced solid tumors (like lung, breast, or ovarian cancer) that have not improved with standard treatments. The goal is to find the best dose and see if it can shrink tumors. About 1,410 participants will receive the drug…

This study tests a combination of two drugs—nivolumab (an immunotherapy that helps the immune system attack cancer) and temozolomide (a chemotherapy that kills cancer cells)—in people with advanced small-cell lung cancer or neuroendocrine tumors that have come back or stopped res…

This early-stage study tests a combination of three drugs (tarlatamab, YL201, and an anti-PD-L1) in about 200 adults with extensive stage small cell lung cancer that has worsened after initial treatment. The main goal is to check safety and side effects, while also measuring how …

This study tests a drug called XmAb20717 in 140 adults with advanced rare cancers, including mesothelioma, cervical cancer, and Hodgkin's lymphoma. The goal is to see if the drug can shrink tumors and how safe it is. Participants must have measurable disease and be able to follow…

This study is testing a new type of PET/CT scan that uses a special tracer (68Ga-DOTATOC) to find neuroendocrine tumors and other related cancers. The goal is to see if this scan is safer and more sensitive than current imaging methods. About 800 people with known or suspected tu…

This study looks at adults with certain cancers (like lung, breast, kidney, or melanoma) that have spread to the brain. All participants are also receiving immunotherapy. The goal is to see if giving a lower dose of radiation over a few days causes fewer side effects than the sta…

This study tests a new program to help adults with lung cancer improve their quality of life after finishing cancer treatment. About 21 people will take part to see if the program is practical and acceptable. The goal is to support patients as they move from active treatment to r…

This study follows over 2,700 patients with bladder, lung, or liver cancer who are receiving the drug atezolizumab as part of their normal care. Researchers are tracking how long patients live and how well the drug controls their cancer outside of a controlled trial setting. The …